Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iBio, Inc.IBIO · Entity 6906 | Chief Scientific Officer | February 20, 2019 | May 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iBio, Inc.
Report date February 20, 2019 · Filed May 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2020-07-14 | Direct | 22,500 |
Reported balance
After 2019-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-20 · Disposition to issuer · Disposed 10,000 · Balance 22,500 F4: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1: Vested in three equal annual instalments on the anniversary of the date of grant. F3: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2024-02-20 | Direct | 22,500 |
Reported balance
After 2019-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-20 · Grant · Acquired 7,500 · Balance 22,500 F5: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F2: Fully vests on first anniversary of grant date. F3: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2021-10-21 | Direct | 22,500 |
Reported balance
After 2019-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-20 · Disposition to issuer · Disposed 10,000 · Balance 22,500 F4: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1: Vested in three equal annual instalments on the anniversary of the date of grant. F3: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2024-02-20 | Direct | 22,500 |
Reported balance
After 2019-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-20 · Grant · Acquired 7,500 · Balance 22,500 F5: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F2: Fully vests on first anniversary of grant date. F3: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2025-09-04 | Direct | 22,500 |
Reported balance
After 2019-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-20 · Disposition to issuer · Disposed 10,000 · Balance 22,500 F4: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1: Vested in three equal annual instalments on the anniversary of the date of grant. F3: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2024-02-20 | Direct | 22,500 |
Reported balance
After 2019-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-20 · Grant · Acquired 7,500 · Balance 22,500 F5: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F2: Fully vests on first anniversary of grant date. F3: Reflects number of securities beneficially owned following all transactions reported on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Vested in three equal annual instalments on the anniversary of the date of grant.
F2: Fully vests on first anniversary of grant date.
F3: Reflects number of securities beneficially owned following all transactions reported on this Form 4.
F4: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.
F5: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2019 Filed May 13, 2019 15:27 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 7,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000502 · doc4_6061.xml · derivative · entry 6 TERENCE RYAN E · CIK 0001557364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F2 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:27 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $17.20 | Not disclosed |
DisclosureSEC source: 0001638599-19-000502 · doc4_6061.xml · derivative · entry 5 TERENCE RYAN E · CIK 0001557364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 10,000 shares Expires 2025-09-04 F4 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:27 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 7,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000502 · doc4_6061.xml · derivative · entry 4 TERENCE RYAN E · CIK 0001557364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F2 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:27 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $19.60 | Not disclosed |
DisclosureSEC source: 0001638599-19-000502 · doc4_6061.xml · derivative · entry 3 TERENCE RYAN E · CIK 0001557364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 10,000 shares Expires 2021-10-21 F4 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:27 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 7,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000502 · doc4_6061.xml · derivative · entry 2 TERENCE RYAN E · CIK 0001557364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F2 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:27 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $13.80 | Not disclosed |
DisclosureSEC source: 0001638599-19-000502 · doc4_6061.xml · derivative · entry 1 TERENCE RYAN E · CIK 0001557364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 10,000 shares Expires 2020-07-14 F4 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| September 04, 2015 Filed Apr 5, 2017 21:35 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 100,000 | $1.72 Strike: $1.72 | $172,000.00 |
DisclosureSEC source: 0001638599-17-000361 · doc4_4659.xml · derivative · entry 1 TERENCE RYAN E · CIK 0001557364 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 100,000 shares Expires 2025-09-04 F1 · derivative.exercise_date: (1) Vesting starts 7/1/2015, in equal annual installments over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.